Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.

Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, Weaver DT, Menges C, Padval M, McClatchey AI, Xu Q, Testa JR, Pachter JA.

Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.

2.

E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.

Kato T, Sato T, Yokoi K, Sekido Y.

Oncogene. 2017 Sep 28;36(39):5522-5531. doi: 10.1038/onc.2017.147. Epub 2017 May 29.

PMID:
28553954
3.

Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.

Shah NR, Tancioni I, Ward KK, Lawson C, Chen XL, Jean C, Sulzmaier FJ, Uryu S, Miller NL, Connolly DC, Schlaepfer DD.

Gynecol Oncol. 2014 Jul;134(1):104-11. doi: 10.1016/j.ygyno.2014.04.044. Epub 2014 Apr 27.

4.

Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.

You M, Varona-Santos J, Singh S, Robbins DJ, Savaraj N, Nguyen DM.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.

5.

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.

Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR.

Oncogene. 2006 Sep 28;25(44):5960-8. Epub 2006 May 1.

PMID:
16652148
6.

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.

Tanaka K, Osada H, Murakami-Tonami Y, Horio Y, Hida T, Sekido Y.

Cancer Lett. 2017 Jan 28;385:215-224. doi: 10.1016/j.canlet.2016.10.020. Epub 2016 Oct 20.

PMID:
27773750
7.

Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.

François RA, Maeng K, Nawab A, Kaye FJ, Hochwald SN, Zajac-Kaye M.

J Natl Cancer Inst. 2015 May 12;107(8). pii: djv123. doi: 10.1093/jnci/djv123. Print 2015 Aug.

8.

SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.

Iwahori K, Serada S, Fujimoto M, Ripley B, Nomura S, Mizuguchi H, Shimada K, Takahashi T, Kawase I, Kishimoto T, Naka T.

Int J Cancer. 2013 Jan 15;132(2):459-71. doi: 10.1002/ijc.27611. Epub 2012 May 17.

9.

Stem Cell Factor-Based Identification and Functional Properties of In Vitro-Selected Subpopulations of Malignant Mesothelioma Cells.

Blum W, Pecze L, Felley-Bosco E, Wu L, de Perrot M, Schwaller B.

Stem Cell Reports. 2017 Apr 11;8(4):1005-1017. doi: 10.1016/j.stemcr.2017.02.005. Epub 2017 Mar 9.

10.

Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.

Hwang KE, Kim YS, Jung JW, Kwon SJ, Park DS, Cha BK, Oh SH, Yoon KH, Jeong ET, Kim HR.

Oncotarget. 2015 Oct 6;6(30):29482-96. doi: 10.18632/oncotarget.5022.

11.

In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.

Muscella A, Vetrugno C, Cossa LG, Antonaci G, De Nuccio F, De Pascali SA, Fanizzi FP, Marsigliante S.

PLoS One. 2016 Nov 2;11(11):e0165154. doi: 10.1371/journal.pone.0165154. eCollection 2016.

12.

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, Sekhon HS, Goss GD, Sabourin LA, Dimitroulakos J, Addison CL.

PLoS One. 2016 Mar 10;11(3):e0150567. doi: 10.1371/journal.pone.0150567. eCollection 2016.

13.

Gli as a novel therapeutic target in malignant pleural mesothelioma.

Li H, Lui N, Cheng T, Tseng HH, Yue D, Giroux-Leprieur E, Do HT, Sheng Q, Jin JQ, Luh TW, Jablons DM, He B.

PLoS One. 2013;8(3):e57346. doi: 10.1371/journal.pone.0057346. Epub 2013 Mar 6.

14.

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.

Kanteti R, Riehm JJ, Dhanasingh I, Lennon FE, Mirzapoiazova T, Mambetsariev B, Kindler HL, Salgia R.

Sci Rep. 2016 Sep 13;6:32992. doi: 10.1038/srep32992.

15.

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling.

López-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG.

Mol Cell Biol. 2009 Aug;29(15):4235-49. doi: 10.1128/MCB.01578-08. Epub 2009 May 18.

16.

Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model.

Abu Lila AS, Kato C, Fukushima M, Huang CL, Wada H, Ishida T.

Int J Oncol. 2016 Apr;48(4):1399-407. doi: 10.3892/ijo.2016.3367. Epub 2016 Feb 1.

PMID:
26847426
17.

Restoration of TRAIL-induced apoptosis in resistant human pancreatic cancer cells by a novel FAK inhibitor, PH11.

Dao P, Smith N, Scott-Algara D, Garbay C, Herbeuval JP, Chen H.

Cancer Lett. 2015 Apr 28;360(1):48-59. doi: 10.1016/j.canlet.2015.02.016. Epub 2015 Feb 12.

PMID:
25684663
18.

The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.

Begum A, Ewachiw T, Jung C, Huang A, Norberg KJ, Marchionni L, McMillan R, Penchev V, Rajeshkumar NV, Maitra A, Wood L, Wang C, Wolfgang C, DeJesus-Acosta A, Laheru D, Shapiro IM, Padval M, Pachter JA, Weaver DT, Rasheed ZA, Matsui W.

PLoS One. 2017 Jul 10;12(7):e0180181. doi: 10.1371/journal.pone.0180181. eCollection 2017.

19.

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.

Mol Cancer Ther. 2016 Oct;15(10):2357-2369. Epub 2016 Aug 10.

20.

In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.

Hamaguchi N, Hamada H, Miyoshi S, Irifune K, Ito R, Miyazaki T, Higaki J.

Cancer Sci. 2010 Sep;101(9):1955-64. doi: 10.1111/j.1349-7006.2010.01632.x.

Supplemental Content

Support Center